Long-term efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ: Relationship of progression to histological response and p53 nuclear accumulation

Journal of Urology

Volumn 157, Issue 5, 1997, Pages 1655-1659

  Ovesen, Henrik ^a   Horn, Thomas ^a   Steven, Kenneth ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

BCG vaccine; bladder neoplasms; carcinoma in situ; protein p53

Indexed keywords

BCG VACCINE; PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GROWTH; CANCER SURVIVAL; CARCINOMA IN SITU; DISEASE COURSE; DRUG RESPONSE; FEMALE; HISTOPATHOLOGY; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN DETERMINATION;

EID: 0030934012     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)64825-0     Document Type: Article

References (23)

1. Althausen, A. F., Prout, G. R., Jr. and Daly, J. J.: Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J. Urol., 116: 575, 1976.
2. Prout, G. R., Jr., Griffin, P. P. and Daly, J. J.: The outcome of conservative treatment of carcinoma in situ of the bladder. J. Urol., 138: 766, 1987.
3. Harland, S. J., Charig, C. R., Highman, W., Parkinson, M. C. and Riddle, P. R.: Outcome in carcinoma in situ of bladder treated with intravesical bacille Calmette-Guérin. Brit. J. Urol., 70: 271, 1992.
4. Cumming, J. A., Hargreave, T. B., Webb, J. N., McIntyre, M. A. and Chisholm, G. D.: Intravesical Evans bacille Calmette-Guérin in the treatment of carcinoma in situ. Brit. J. Urol., 63: 259, 1989.
5. Herr, H. W., Wartinger, D. D., Fair, W. R. and Oettgen, H. F.: Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year followup. J. Urol., 147: 1020, 1992.
6. Sarkis, A. S., Dalbagni, G., Cordon-Cardo, C., Melamed, J., Zhang, Z.-F., Sheinfeld, J., Fair, W. R., Herr, H. W. and Reuter, V. E.: Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J. Urol., 152: 388, 1994.
7. Nadler, R. B., Catalona, W. J., Hudson, M. A. and Ratliff, T. L.: Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy. J. Urol., 152: 367, 1994.
8. Kerns, B. J., Jordan, P. A., Moore, M. B., Humphrey, P. A., Berchuck, A., Kohler, M. F., Bast, R. C., Jr., Iglehart, J. D. and Marks, J. R.: p53 overexpression in formalin-fixed paraffin-embedded tissue detected by immunohistochemistry. J. Histochem. Cytochem., 40: 1047, 1992.
9. Spruck, C. H., III, Ohneseit, P. F., Gonzalez-Zulueta, M., Esrig, D., Miyao, N., Tsai, Y. C., Lerner, S. P., Schmutte, C., Yang, A. S. and Cote, R.: Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res., 54: 784, 1994.
10. Ovesen, H., Poulsen, A. L. and Steven, K.: Intravesical bacillus Calmette-Guerin with the Danish strain for treatment of carcinoma in situ of the bladder. Brit. J. Urol., 72: 744, 1993.
11. Kamat, M. R., Kulkarni, J. N., Tongaonkar, H. B. and Dalal, A. V.: Intravesical bacillus Calmette-Guerin for superficial bladder cancer: experience with the Danish 1331 strain. J. Urol., 152: 1424, 1994.
12. Bergquist, A., Lungquist, A. and Moeberger, G.: Classification of bladder tumors based on the cellular pattern. Acta Chir. Scand., 130: 371, 1965.
13. Kaplan, E. L. and Meier, P.: Nonparametric estimation from incomplete observations. J. Amer. Stat. Assoc., 53: 457, 1958.
14. Hosmer, D. W. and Lemeshow, S.: Applied Logistic Regression. New York: John Wiley & Sons, 1989.
15. Catalona, W. J., Hudson, M. A., Gillen, D. P., Andriole, G. L. and Ratliff, T. L.: Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J. Urol., 137: 220, 1987.
16. Coplen, D. E., Marcus, M. D., Myers, J. A., Ratliff, T. L. and Catalona, W. J.: Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor. J. Urol., 144: 652, 1990.
17. Merz, V. W., Marth, D., Kraft, R., Ackermann, D. K., Zingg, E. J. and Studer, U. E.: Analysis of early failures after intravesical instillation therapy with bacille Calmette-Guerin for carcinoma in situ of the bladder. Brit. J. Urol., 75: 180, 1995.
18. Dalbagni, G., Lacombe, L., Fair, W. R., Herr, H. W. and Reuter, V. E.: Evaluation of p53 expression in superficial bladder tumors before and after BCG, and comparison to clinical outcome. J. Urol., part 2, 153: 363A, abstract 538, 1995.
19. Esrig, D., Spruck, C. H., Nichols, P. W., Chaiwun, B., Steven, K., Groshen, S., Chen, S. C., Skinner, D. G., Jones, P. A. and Cote, R. J.: p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade and stage in bladder cancer. Amer. J. Path., 143: 1389, 1993.
20. Tsai, Y. C., Simoneau, A. R., Spruck, C. H., III, Nichols, P. W., Steven, K., Buckley, J. D. and Jones, P. A.: Mosaicism in human epithelium: macroscopic monoclonal patches cover the urothelium. J. Urol., 153: 1697, 1995.
21. Norming, U., Tribukait, B., Gustafson, H., Nyman, C. R., Wang, N. and Wijkström, H.: Deoxyribonucleic acid profile and tumor progression in primary carcinoma in situ of the bladder: a study of 63 patients with grade 3 lesions. J. Urol., 147: 11, 1992.
22. Heney, N. M., Ahmed, S., Flanagan, M. J., Frable, W., Corder, M. P., Hafermann, M. D. and Hawkins, I. R. for National Bladder Cancer Collaborative Group A: Superficial bladder cancer: Progression and recurrence. J. Urol., 130: 1083, 1983.
23. Norming, U., Tribukait, B., Nyman, C. R., Nilsson, B. and Wang, N.: Prognostic significance of mucosal aneuploidy in stage Ta/T1 grade 3 carcinoma of the bladder. J. Urol., 148: 1420, 1992.